49BA:F:F-BeiGene Ltd (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 191

Change

0.00 (0.00)%

Market Cap

USD 22.99B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
RGO:F Regeneron Pharmaceuticals Inc

-5.60 (-0.72%)

USD 84.33B
CSJ:F CSL Limited

+0.14 (+0.08%)

USD 83.49B
CSJA:F CSL LTD SPON.ADR 2

+1.50 (+1.73%)

USD 82.40B
UNC0:F UCB S.A. UNSP.ADR 1/2

-4.00 (-4.26%)

USD 34.23B
1AE:F Argen-X

-14.40 (-2.57%)

USD 33.52B
1AEA:F argenx SE

-5.00 (-0.91%)

USD 33.15B
DUL:F Alnylam Pharmaceuticals Inc

-2.50 (-0.96%)

USD 32.23B
22UA:F BioNTech SE

-2.80 (-2.72%)

USD 24.86B
49B:F BeiGene Ltd.

-0.50 (-3.40%)

USD 21.35B
0QF:F Moderna Inc

+0.65 (+1.62%)

USD 16.69B

ETFs Containing 49BA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.90% 69% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.90% 69% C- 69% C-
Trailing 12 Months  
Capital Gain 4.95% 53% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.95% 53% F 47% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.30% 51% F 27% F
Dividend Return -6.30% 50% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.32% 63% D 45% F
Risk Adjusted Return -21.48% 50% F 30% F
Market Capitalization 22.99B 98% N/A 92% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.